259 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
7 May 24
Ligand Reports First Quarter 2024 Financial Results
4:03pm
in 2023, with the change due to the timing of customer orders. Contract revenue and other income was $2.7 million for the first quarter of 2024
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
to the timing of customer orders. There were no Captisol sales related to COVID-19 in 2023, compared with $88.1 million in 2022. Contract revenue for 2023
8-K/A
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
9 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
9:48pm
quarter of 2023, compared with $3.6 million for the same period in 2022, with the increase due to the timing of customer orders. There were no Captisol … in 2022. The difference in sales was due to the timing of customer orders. There were no Captisol sales related to COVID-19 for the nine months ended
8-K
EX-99.1
1z8v5izf0ei
8 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
4:08pm
8-K
EX-10.1
l1d7lmakca fy86zn7gq
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
8-K
EX-99.1
ftwylat6 8ut
8 Aug 23
Ligand Reports Second Quarter 2023 Financial Results
4:02pm
8-K
EX-99.1
ye5kp15dv80j
4 May 23
Ligand Reports First Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
bsdfy74jb
7 Nov 22
Ligand Reports Third Quarter 2022 Financial Results
4:04pm
S-3ASR
EX-1.2
smyzu7g4
30 Sep 22
Automatic shelf registration
4:17pm
8-K
EX-99.1
tystedvnohk37ttobl94
8 Aug 22
Ligand Reports Second Quarter 2022 Financial Results
4:06pm
425
evlx989 or
5 May 22
Business combination disclosure
7:30am
8-K
EX-99.1
7ril400
4 May 22
Ligand Reports First Quarter 2022 Financial Results
4:03pm
425
edlv16w6msm
24 Mar 22
Business combination disclosure
9:09am